Betta Pharmaceuticals Co., Ltd. cancelled the acquisition of remaining 22.6% stake in AnewPharma Company, Ltd. from Shanghai Zhangjiang Biomedical Industry Venture Capital Co., Ltd. and Shanghai Zhangjiang Technology Venture Capital Co., Ltd.
June 15, 2018
Share
Betta Pharmaceuticals Co.,Ltd (SZSE:300558) won the bid and signed an agreement to acquire remaining 22.6% stake in AnewPharma Company, Ltd. from Shanghai Zhangjiang Biomedical Industry Venture Capital Co., Ltd. and Shanghai Zhangjiang Technology Venture Capital Co., Ltd. for approximately CNY 110 million on June 16, 2017. AnewPharma Company, Ltd. reported total assets of CNY 16.9 million, net assets of CNY 16.3 million, revenue of CNY 0 million, operating loss of CNY 13.9 million and net loss of CNY 10.9 million for the year ended December 31, 2016.
Betta Pharmaceuticals Co., Ltd. (SZSE:300558) cancelled the acquisition of remaining 22.6% stake in AnewPharma Company, Ltd. from Shanghai Zhangjiang Biomedical Industry Venture Capital Co., Ltd. and Shanghai Zhangjiang Technology Venture Capital Co., Ltd. on June 16, 2018.
Betta Pharmaceuticals Co Ltd is a company mainly engaged in research, development, production and sales of innovative drugs for the treatment of malignant tumors. The Company's primary product is its self-developed icotinib hydrochloride (Conmana), a small molecule targeted anticancer drug used for the treatment of lung cancer. The Company is also engaged in promotional services, real estate leasing and other businesses.
Betta Pharmaceuticals Co., Ltd. cancelled the acquisition of remaining 22.6% stake in AnewPharma Company, Ltd. from Shanghai Zhangjiang Biomedical Industry Venture Capital Co., Ltd. and Shanghai Zhangjiang Technology Venture Capital Co., Ltd.